The Molecular Screening Shared Resource (MSSR): Completion of the genome sequences of humans, mice, zebrafish and a number of other model organisms has led to the tentative identification of all encoded proteins in these species. The proliferation both of chemical libraries and of libraries of genome wide inhibitory RNA sequences for a number of species has made it possible to conceive of looking for inhibitory small molecules and inhibitory RNAs for all genetically encoded targets. The concomitant development of High Throughput Screening (NTS) technologies has made it possible - with the right resources - to move this from concept to practice. The UCLA JCCC Molecular Screening Shared Resource (MSSR) was established in 2003 to meet this exciting scientific objective. The MSSR now has dedicated space in the new California NanoSystems Institute, small molecule libraries containing over 70,000 compounds, genomewide knockout libraries for yeast, and interfering RNA libraries for both murine and human targets. Excellent academic and technical leadership has established a robust, accessible screening center that assists both in developing reliable and robust enzymatic and cell culture HTS assays and in facilitating genome-wide screens. The David Geffen School of Medicine, the California NanoSystems Institute (CNSI), the UCLA College of Letters and Science, several individual departments and some private donors have joined the JCCC to provide funding for the equipment and libraries (well over $1,000,000) and operating "start-up" required to get the MSSR up and running. The Shared Resource has run (or is currently running) 65 screens, the great majority of which are for JCCC members. Members of the Gene Regulation, Signal Transduction and Therapeutics, Tumor Immunology, Cancer Cell Biology, Hematopoietic Malignancies, Developing Program in Molecular Epidemiology and Carcinogenesis, Thoracic Oncology and Genitourinary Oncology Program Areas have already utilized this Shared Resource. The CCSG budget request for this Shared Resource for the first year CCSG budget is for 13% of the estimated operating budget;support for the shared resource also comes from the CNSI, an NIH Center for Radioprotectors, the UCLA Chancellor's Biosciences Initiative, user recharges and philanthropy. (Please also see Section 6.2.3 on Shared Resources in the History, Description, Essential Characteristics). Eight Cancer Center members representing four Cancer Center Program Areas completed screens in the Molecular Screening Shared Resource during the reporting period;many screens are ongoing. This is a continuing shared resource.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016042-38
Application #
8392137
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
38
Fiscal Year
2013
Total Cost
$168,383
Indirect Cost
$66,159
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Li, Gang; Lu, Xuyang (2015) A Bayesian approach for instrumental variable analysis with censored time-to-event outcome. Stat Med 34:664-84
Epeldegui, Marta; Blom, Bianca; Uittenbogaart, Christel H (2015) BST2/Tetherin is constitutively expressed on human thymocytes with the phenotype and function of Treg cells. Eur J Immunol 45:728-37
Bower, Julienne E; Crosswell, Alexandra D; Stanton, Annette L et al. (2015) Mindfulness meditation for younger breast cancer survivors: a randomized controlled trial. Cancer 121:1231-40
Arensman, Michael D; Telesca, Donatello; Lay, Anna R et al. (2014) The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth. Mol Cancer Ther 13:2303-14
Li, Keyu; Tavaré, Richard; Zettlitz, Kirstin A et al. (2014) Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments. Mol Cancer Ther 13:2607-17
Ke, Ruian; Loverdo, Claude; Qi, Hangfei et al. (2014) Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration. J Antimicrob Chemother 69:724-7
Fu, Maoyong; Maresh, Erin L; Helguera, Gustavo F et al. (2014) Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer. Mol Cancer Ther 13:902-15
Leoh, Lai Sum; Morizono, Kouki; Kershaw, Kathleen M et al. (2014) Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter. J Gene Med 16:11-27
Tong, Maomeng; McHardy, Ian; Ruegger, Paul et al. (2014) Reprograming of gut microbiome energy metabolism by the FUT2 Crohn's disease risk polymorphism. ISME J 8:2193-206
Wong, Deborah J L; Rao, Amol; Avramis, Earl et al. (2014) Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function. Cancer Immunol Res 2:459-68

Showing the most recent 10 out of 192 publications